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ABSTRACT
Introduction: Sleep is essential for overall
health and well-being, yet more than one-third
of adults report inadequate sleep. The preva-
lence is higher among people with psoriasis,
with up to 85.4% of the psoriatic population
reporting sleep disruption. Poor sleep among
psoriasis patients is particularly concerning
because psoriasis is independently associated
with many of the same comorbidities as sleep
dysfunction, including cardiovascular disease,
obesity, and depression. Given the high
prevalence and serious consequences of disor-
dered sleep in psoriasis, it is vital to understand
the nature of sleep disturbance in this popula-
tion. This study was designed to help meet this
need by using survey data from Citizen Pscien-
tist, an online patient portal developed by the
National Psoriasis Foundation.
Methods: Our analysis included 3118 partici-
pants who identified as having a diagnosis by a
physician of psoriasis alone or psoriasis with
psoriatic arthritis. Demographic information,
psoriasis severity and duration, sleep apnea
status, smoking and alcohol consumption, itch
timing, and sleep characteristics were included.
Two separate multivariate logistic regression
models in STATA were used to determine whe-
ther the presence of psoriatic arthritis, age,
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gender, body mass index, comorbid sleep
apnea, psoriasis severity, timing of worst itch,
smoking status, or high-risk alcohol consump-
tion were associated with sleep difficulty or low
sleep quantity, defined by the American Acad-
emy of Sleep Medicine as less than 7 h of sleep
per night on average.
Results: Results from the multivariate logistic
regressions found that sleep difficulty was
associated with psoriatic arthritis (OR 2.15, 95%
CI [1.79–2.58]), female gender (2.03
[1.67–2.46]), obese body mass index (BMI C 30)
(1.25 [1.00–1.56]), sleep apnea (1.41
[1.07–1.86]), psoriasis severity of moderate (1.59
[1.30–1.94]) or severe (2.40 [1.87–3.08]), and
smoking (1.60 [1.26–2.02]). Low sleep quantity
was associated with obese BMI (1.62
[1.29–2.03]), sleep apnea (1.30 [1.01–1.68]),
psoriasis severity of moderate (1.41 [1.16–1.72])
or severe (1.40 [1.11–1.76]), and smoking (1.62
[1.31–2.00]). Sleep difficulty and low sleep
quantity were not associated with age, alcohol
consumption, or timing of worst itch.
Conclusion: These results are potentially
meaningful in several aspects. We identify an
important distinction between sleep difficulty
and sleep quantity in psoriatic disease,
whereby having psoriatic arthritis and being
female are each associated with sleep difficulty
despite no association with low sleep quantity.
Furthermore, there is conflicting evidence
from prior studies as to whether psoriasis
severity is associated with sleep difficulty, but
this well-powered, large study revealed a
strong, graded relationship between psoriasis
severity and both sleep difficulty and low
sleep quantity. Overall, our results show that
both sleep difficulty and low sleep quantity
were associated with multiple factors in this
analysis of a large psoriatic cohort. These
findings suggest that dermatologists may
gather clinically useful information by
screening psoriatic patients for trouble sleep-
ing and low sleep quantity to identify poten-
tial comorbidities and to more effectively
guide disease management.
Keywords: Comorbidities; Psoriasis; Sleep;
Survey research
INTRODUCTION
Chronic sleep dysfunction can lead to a wide
variety of adverse health outcomes, including
cardiovascular disease, hypertension, obesity,
type 2 diabetes mellitus, depression, and all-
cause mortality [1, 2]. In addition to these long-
term consequences, sleep disturbance can pro-
foundly affect daily functioning, contributing
to difficulty concentrating, impaired school or
work performance, and driving or transporta-
tion accidents [3, 4]. Sleep is therefore essential
for overall health and well-being [5], yet more
than one-third of adults in the USA report
inadequate sleep [6]. The prevalence is remark-
ably higher among people with psoriasis
[5, 7–11]. For examples, a 2005 survey found
that 49.5% of psoriasis patients experience sleep
interference [7], a 2008 case–control study
concluded that disordered sleep is a significant
comorbidity in psoriasis [12], and a 2016 sys-
tematic review and meta-analysis reported sleep
disruption in up to 85.4% of the psoriatic pop-
ulation [10]. Moreover, people with psoriasis are
more likely to have diagnosed sleep-related
conditions such as obstructive sleep apnea
(OSA) (36.0–81.8% prevalence in psoriasis ver-
sus 2–4% in the general population), restless
legs syndrome (15.1–18.0% versus 5–10%), and
transient or chronic insomnia (5.9–44.8% ver-
sus 10–53%) [13].
Poor sleep among psoriasis patients is par-
ticularly concerning because psoriasis is inde-
pendently associated with many of the same
comorbidities as sleep dysfunction [12–14]. The
consequences of each condition can thereby
compound, with deadly results. In fact, a 2016
cohort study found that psoriasis patients with
concomitant sleep disorders had significantly
higher risks of ischemic heart and stroke events
as compared to psoriasis patients without sleep
issues [8]. In this way, disordered sleep does not
merely reduce quality of life in psoriasis but can
result in potentially lethal health outcomes.
Given the high prevalence and serious con-
sequences of disordered sleep in psoriasis, it is
vital to better understand the nature of sleep
disturbance in this population. Contributing
factors can be divided into two categories:
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insufficient quantity of sleep and poor quality
of sleep. The former is defined as less 7 h of
sleep per day on average, as recommended by
the American Academy of Sleep Medicine [4].
This measure can be readily assessed by directly
asking an individual to quantify their average
sleep. On the other hand, assessing sleep quality
is far more complex. Sleep quality is determined
by several factors, including but not limited to
sleep latency, continuity, depth, and post-sleep
restoration [15, 16]. An individual may have a
subjective sense of their sleep quality and can be
screened by asking if they experience difficulty
or trouble sleeping on a routine basis, but many
require objective evaluation using
polysomnography and other specialized meth-
ods. Such evaluations are relatively simple and
have been studied in association with many
medical conditions, but it remains a critical
need to more rigorously study sleep disturbance
among large numbers of patients living with
psoriatic disease [17].
This study was designed to help meet this
need. Citizen Pscientist (CP) is an online patient
portal developed by the National Psoriasis
Foundation (NPF) that is designed to provide
psoriatic patients with an opportunity to con-
nect with each other by completing an optional
survey with questions including demographic
details, symptom and treatment histories, and
quality of life topics such as the impact of their
condition on diet, exercise, and of course sleep
[18]. Participation in CP is completely volun-
tary. For those who opt in, CP participants can
perform their own analyses of responses to the
CP survey since all answers are posted to the CP
website without any identifying information of
those who provided it [18]. Participants also
have the option to comment on survey results
and engage in discussions with other members
of the CP community, which has participants
around the world [19].
Furthermore, clinicians and researchers can
request access to this de-identified data to
inform clinical care and research initiatives. The
study described here used CP survey data as of
July 2018 to examine what factors are associated
with sleep difficulty and sleep quantity in this
psoriatic cohort.
METHODS
Our analysis included data from 3118 partici-
pants who completed the CP survey and iden-
tified as having a diagnosis by a physician of
psoriasis alone or psoriasis with psoriatic
arthritis. Institutional review board (IRB)
approval for CP was obtained from Genetic
Alliance, which includes participants outside of
the USA as included in this cohort. The study
conformed with the Helsinki Declaration of
1964, as revised in 2013, concerning human
rights. Participants had access to the Terms and
Conditions of CP, including statements regard-
ing the unlikely possibility that a breach of data
confidentiality may occur and that their survey
responses may be analyzed by researchers
studying psoriatic disease and may be presented
in written publications [18].
The most recent version of the CP survey
contains 79 questions. A subset of 15 questions
were selected for the scope of this analysis
(Table 1). Demographic information, psoriasis
severity and duration, sleep apnea status,
smoking and alcohol consumption, itch timing,
and sleep characteristics are provided (Table 2).
Psoriasis severity was participant-reported by
answering the survey question about psoriasis
body surface (BSA) area involvement. Mild was
defined as BSA less than 5%, moderate was
defined as BSA of 5–10%, and a BSA greater than
10% was defined as severe. Sleep characteristics
were derived from survey questions about hours
of sleep per day on average and trouble sleeping.
Participants who reported sleeping less than 7 h
per day on average were categorized as having
low sleep quantity, as defined by the American
Academy of Sleep Medicine [4], and participants
who responded ‘‘yes’’ to the question ‘‘Do you
have trouble sleeping?’’ were categorized as
having sleep difficulty.
STATA software (version 15) was used to
tabulate frequencies, percentages, and means,
and two separate multivariate logistic regression
models were used to determine whether the
presence of psoriatic arthritis, age, gender, body
mass index (BMI), comorbid sleep apnea, pso-
riasis severity, timing of worst itch, smoking
status, or high-risk alcohol consumption were
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Table 1 Subset of Citizen Pscientist survey questions and response options
Question Response options
Has a doctor diagnosed you
with psoriasis?
Yes, No
Has a doctor diagnosed you
with psoriatic arthritis?
Yes, No
How old are you? Under 18, 18–25, 26–30, 31–35, 36–40, 41–45, 46–50, 51–55, 56–60, 61–65, Over 65
What is your sex? Male, Female
How tall are you? Under 4.5 ft, 4.5 ft–5 ft, Over 5 ft–5.5 ft, Over 5.5 ft–6 ft, Over 6 ft–6.5 ft, Over 6.5 ft
How much do you weigh? Under 100 lbs, 100–120 lbs, 121–140 lbs, 141–160 lbs, 161–180 lbs, 181–200 lbs,
201–220 lbs, 221–240 lbs, 241–260 lbs, 261–280 lbs, 281–300 lbs, 301–320 lbs,
321–340 lbs, 341–360 lbs, 361–380 lbs, 381–400 lbs, Over 400 lbs
Do you have one or more of
the following conditions?
Crohn’s disease, Juvenile-onset diabetes (type 1), Rheumatoid arthritis, Lupus, Eczema,
Cutaneous T cell lymphoma, Celiac disease, Sjogren’s syndrome, Uveitis, Thyroid
disease, Multiple sclerosis, Alopecia areata, Atopic dermatitis, High cholesterol, High
triglycerides, High blood pressure, Coronary artery disease, Stroke, Adult-onset
diabetes (type 2), Parkinson’s disease, Liver disease, Cancer, Sleep apnea, Fatty liver
disease
How much of your body is
covered by psoriasis?
None or very little (body surface area, BSA\ 5%), Only a few patches that could be
covered by 1 or 2 palms of your hand (BSA\ 5%), Could be covered by less than 5
palms of your hand (BSA\ 5%), Between 5 and 10 palms of your hand (BSA
5–10%), Scattered patches (BSA 5–10%), Covered by more than 10 palms of your
hand (BSA[ 10%), Extensive psoriasis (BSA[ 10%)
At what age did a doctor
diagnose you with psoriasis?
I have never been diagnosed with psoriasis by a doctor, Under 18, 18–25, 26–30, 31–35,
36–40, 41–45, 46–50, 51–55, 56–60, 61–65, Over 65
At what age did a doctor
diagnose you with psoriatic
arthritis?
I have never been diagnosed with psoriatic arthritis by a doctor, Under 18, 18–25,
26–30, 31–35, 36–40, 41–45, 46–50, 51–55, 56–60, 61–65, Over 65
How many cigarettes do you
smoke per day?
I don’t smoke, I only smoke occasionally, 1–10 cigarettes, 11–20 cigarettes, More than
20 cigarettes
How many alcoholic drinks do
you have per week? (one
drink is 12 oz beer, 5 oz
wine, 1 oz of liquor)
I don’t drink alcohol, 1–3, 4–6, 7–9, 10 or more
At what time of day do you
experience the most itch?
Morning, Midday, Afternoon, Evening, Night
Do you have trouble sleeping at
night?
Yes, No
How many hours of sleep do
you get per day on average?
Under 5 h, 5 h, 6 h, 7 h, 8 h, 9 h, 10 or more hours
514 Dermatol Ther (Heidelb) (2019) 9:511–523
associated with sleep difficulty or low sleep
quantity (Table 3). The dependent variables lis-
ted above were chosen a priori, and both mod-
els were evaluated and adjusted for statistical
interactions. For each outcome, p values of less
than 0.05 were deemed significant, and odds
ratios (ORs) with 95% confidence intervals (CIs)
are reported.
RESULTS
Demographic results and clinical characteristics
(Table 2) demonstrate that the CP population is
almost equally composed of participants with
psoriasis only (n = 1588, 50.9%) and those with
psoriatic arthritis (n = 1530, 49.1%). As previ-
ously described, the CP psoriatic cohort is
approximately 70% White/Caucasian [19]. This
population is predominantly female (n = 2153,
69.1%), and the mean age is 45.2 (standard
deviation 0.3). The average BMI is 27.6 (stan-
dard deviation 0.3), and 62.8% of participants
have an overweight or obese BMI. With respect
to disease duration, more than 10 years was
reported by the majority of both psoriasis
(80.3%) and psoriatic arthritis (69.5%) partici-
pants. In terms of sleep characteristics, over half
of participants reported sleep difficulty (58.4%),
and low sleep quantity was reported by 38.8%
of respondents. More specifically, the propor-
tions of participants endorsing each survey
response option for sleep duration are illus-
trated in Fig. 1.
Results from the multivariate logistic regres-
sions (Table 3) found that sleep difficulty was
associated with psoriatic arthritis (OR 2.15, 95%
CI [1.79–2.58]), female gender (2.03
[1.67–2.46]), obese body mass index (BMI C 30)
(1.25 [1.00–1.56]), sleep apnea (1.41
[1.07–1.86]), psoriasis severity of moderate (1.59
[1.30–1.94]) or severe (2.40 [1.87–3.08]), and
smoking (1.60 [1.26–2.02]). Low sleep quantity
was associated with obese BMI (1.62
[1.29–2.03]), sleep apnea (1.30 [1.01–1.68]),
psoriasis severity of moderate (1.41 [1.16–1.72])
or severe (1.40 [1.11–1.76]), and smoking (1.62
[1.31–2.00]). Sleep difficulty and low sleep
quantity were not associated with age, alcohol
consumption, or timing of worst itch.
DISCUSSION
These results are potentially meaningful in
several aspects. First, we identify an important
distinction between sleep difficulty and sleep
quantity in psoriatic disease, whereby having
psoriatic arthritis and being female are each
associated with sleep difficulty despite no asso-
ciation with low sleep quantity. It is not possi-
ble to definitively account for these differences
from this analysis, but various potential expla-
nations can be considered. It is feasible that
psoriatic arthritis contributes to musculoskele-
tal discomfort that causes more sleep difficulty
than the cutaneous symptoms of psoriasis
alone. Such physical discomfort might not
reduce the number of hours slept on average but
may cause trouble initiating and staying asleep
or feeling rested after a sufficient quantity of
sleep [7], which may be reported by CP partici-
pants as sleep difficulty despite adequate sleep
quantity. With respect to gender, an extensive
literature review indicates that this is the first
study to report that female gender is uniquely
associated with sleep difficulty in psoriatic
patients. It is conceivable that women with
psoriasis are more likely to report trouble
sleeping because they tend to be more attuned
to less restorative sleep, as reported in the gen-
eral population [20]. Thus, even though women
with psoriasis report similar quantity of sleep as
their male counterparts, the former might not
be sleeping as soundly as the latter who also
may be less aware of any problem.
Second, there is conflicting evidence from
prior studies as to whether psoriasis severity is
associated with sleep difficulty [7, 9], but this is
a well-powered, large study that revealed a
strong, graded relationship between psoriasis
severity and both sleep difficulty and low sleep
quantity. These associations are reasonable
given that more severe physical symptoms of
psoriasis, especially pruritus [21], are more dis-
ruptive to a person’s ability to sleep without
difficulty, delayed onset, or premature cessa-
tion. Likewise, a 2008 study found that
impaired sleep quality can partly mediate the
association between pruritus and psychological
symptoms in psoriasis, including anxiety and
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depression [22]. Such psychological comorbidi-
ties are more common in moderate and severe
psoriasis and also independently associated
with sleep disturbance [11, 23–26]. Therefore,
sleep problems in psoriasis may be due to a
combination of disease severity, as seen in this
study, as well as closely related psychological
factors that undoubtedly play a role in these
associations but that were outside the scope of
the CP survey.
Table 2 Clinical and sleep characteristics
Characteristic Frequency (%)
Disease
Psoriasis 1588 (50.9)
Psoriasis with psoriatic arthritis 1530 (49.1)
Age
18–20 142 (4.6)
21–30 248 (8.0)
31–40 559 (17.9)
41–50 696 (22.3)
51–60 806 (25.8)
61–70 653 (20.9)
71–80 8 (0.3)
81–90 5 (0.2)
91–99 1 (0.1)
Gender
Male 960 (30.8)
Female 2153 (69.1)
No response 5 (0.1)
Body mass index (BMI)
Underweight (\ 18.5) 137 (4.4)
Normal (18.5–24.9) 1021 (32.8)
Overweight (25–29.9) 875 (28.1)
Obese (C 30) 1085 (34.8)
Comorbid sleep apnea
Absent 2735 (87.7)
Present 383 (12.3)
Psoriasis severity
Mild (\ 5% body surface area) 1328 (45.1)
Moderate (5–10% body surface area) 1053 (35.8)
Severe ([ 10% body surface area) 564 (19.2)
Disease duration
Psoriatic skin disease
0–10 years 613 (19.7)
[ 10 years 2505 (80.3)
Table 2 continued
Characteristic Frequency (%)
Psoriatic arthritis
0–10 years 466 (30.5)
[ 10 years 1064 (69.5)
Smoking status
Non-smoker 2416 (80.3)
Smoker 594 (19.7)
Alcohol consumption
Low-risk 2710 (89.7)
High-risk 311 (10.3)
Timing of Worst Itch Frequency (%)
Do not notice a difference 202 (6.5)
Morning 363 (11.6)
Midday 307 (9.8)
Afternoon 349 (11.1)
Evening 1048 (33.7)
Night 863 (27.6)
Sleep characteristics Frequency (%)
Sleep quality
No trouble sleeping 1213 (41.6)
Trouble sleeping 1704 (58.4)
Sleep quantity
Less than 7 h per day 1166 (38.8)
7 h or more per day 1836 (61.2)
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Table 3 Factors associated with sleep difficulty or low sleep quantity by multivariate logistic regression
Variable OR 95% CI p value
Sleep difficultya
Disease
Psoriasis without psoriatic arthritis – – –
Psoriasis with psoriatic arthritis 2.15 1.79–2.58 \ 0.001*
Age 0.99 0.93–1.04 0.671
Gender
Male – – –
Female 2.03 1.67–2.46 \ 0.001*
BMI
Normal BMI – – –
Underweight (\ 18.5) 0.81 0.53–1.24 0.331
Overweight (25–29.9) 1.08 0.86–1.36 0.493
Obese (C 30) 1.25 1.00–1.56 0.047*
Comorbid sleep apnea 1.41 1.07–1.86 0.016*
Psoriasis severity
Mild – – –
Moderate 1.59 1.30–1.94 \ 0.001*
Severe 2.40 1.87–3.08 \ 0.001*
Timing of worst itch
No difference – – –
Morning 1.26 0.62–2.56 0.521
Midday 1.19 0.58–2.43 0.641
Afternoon 1.30 0.64–2.66 0.468
Evening 1.18 0.60–2.33 0.630
Night 1.34 0.68–2.65 0.403
Smoker 1.60 1.26–2.02 \ 0.001*
High-risk alcohol consumption 0.79 0.59–1.05 0.105
Sleep quantityb
Disease
Psoriasis without psoriatic arthritis – – –
Psoriasis with psoriatic arthritis 1.08 0.91–1.29 0.371
Age 1.01 0.96–1.07 0.663
Gender
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Third, it is important to discuss the influence
of OSA status and treatment on these results.
Comorbid OSA was found to be associated with
both sleep difficulty and low sleep quantity.
These findings are consistent with literature on
the relationship between OSA and psoriasis
[9, 13, 27, 28]. At the same time, the CP survey
did not include questions about treatment for
OSA, such as continuous positive airway
pressure (CPAP), that could certainly influence
the relationships between sleep difficulty, sleep
quantity, and psoriasis. Similarly, high BMI was
associated with both sleep variables, but given
the association between being overweight or
obese with OSA and psoriasis [29, 30], the link
between high BMI and poor sleep may be
explained by undiagnosed OSA. Relatedly, prior
studies with smaller psoriatic cohorts have not
Table 3 continued
Variable OR 95% CI p value
Male – – –
Female 1.16 0.95–1.40 0.138
BMI
Normal BMI – – –
Underweight (\ 18.5) 1.15 0.75–1.76 0.527
Overweight (25–29.9) 1.09 0.86–1.38 0.475
Obese (C 30) 1.62 1.29–2.03 \ 0.001*
Comorbid sleep apnea 1.30 1.01–1.68 0.044*
Psoriasis severity
Mild – – –
Moderate 1.41 1.16–1.72 0.001*
Severe 1.40 1.11–1.76 0.004*
Timing of worst itch
No difference – – –
Morning 0.81 0.40–1.63 0.553
Midday 0.96 0.47–1.93 0.900
Afternoon 0.91 0.45–1.84 0.797
Evening 0.98 0.50–1.90 0.943
Night 0.84 0.43–1.65 0.618
Smoker 1.62 1.31–2.00 \ 0.001*
High-risk alcohol consumption 1.34 0.70–2.58 0.372
OR odds ratio, CI confidence interval
*p value of less than 0.05 was deemed to be significant
a Defined as answering ‘‘yes’’ to the survey question ‘‘Do you have trouble sleeping at night?’’
b Defined as answering ‘‘Under 5 h,’’ ‘‘5 h,’’ or ‘‘6 h’’ to the survey question ‘‘How many hours of sleep do you get per day on
average?’’
– Indicates the reference group for each variable
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found obesity to be predictive of sleep interfer-
ence [7], but this analysis demonstrated a strong
relationship between high BMIs and both sleep
difficulty and low sleep quantity.
Limitations
All data used for this analysis were participant-
reported and not physician-confirmed. For
example, psoriasis severity was determined by
patient-reported evaluation of BSA involvement
rather than a physician’s evaluation. Another
example is that OSA status was reported by
patients who may or may not have been for-
mally evaluated for this key sleep-related
comorbidity. This limitation could not be
overcome given the web-based delivery of the
CP survey and the de-identification of survey
responses, making it not possible to link CP
participant responses to physician-reported
data.
Another limitation is that causality cannot
be inferred from the reported associations. This
is a limitation inherent to data from observa-
tional cohort studies at a single time point like
this one. A related limitation is that the design
of this study as an online survey for patients
living with psoriatic disease makes it not possi-
ble to compare the results from participants’
responses to a control group.
An additional limitation is related to the
survey instrument. As discussed, the full CP
survey contains 79 questions that span many
topics related to living with psoriatic disease.
Only two of these questions relate to sleep dif-
ficulty and quantity. While both questions were
included in the subset used for this analysis
(Table 1), it would have been helpful to have
more questions about sleep, such as asking
about non-restorative sleep, sleep timing, or
many other factors that influence sleep quality
and duration. It would have been additionally
helpful to include questions about psychologi-
cal symptoms, such as anxiety or depression
that could also directly impact sleep as descri-
bed above. Using a more extensive, validated
4.9% 5.2%
20.9%
33.3%
24.1%
9.5%
2.1%
Under 5 hours 5 hours 6 hours 7 hours 8 hours 9 hours 10 or more
hours
Hours of Sleep per Day on Average
)
%(stnapicitraPfo
egatnecreP
Sufficient quanty of sleep
(i.e. ≥ 7 hours)
Insufficient quanty of sleep
(i.e. < 7 hours)
*
Fig. 1 Sleep duration responses. *American Academy of Sleep Medicine recommends 7 h as the amount of sleep needed to
promote optimal health in adults [4]
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instrument to evaluate sleep in psoriatic
patients would be appropriate for future studies.
Lastly, the CP participant population lacks
racial, gender, and age diversity. With particular
respect to race, this cohort is approximately
70% White/Caucasian. Although psoriasis is
most common in this group [31], a more
racially diverse cohort would better capture a
broader range of experiences with psoriasis and
sleep.
CONCLUSIONS
Overall, our results show that both sleep diffi-
culty and low sleep quantity were associated
with multiple factors in this analysis of a large
psoriatic cohort. These findings suggest that
dermatologists may gather clinically useful
information by screening psoriatic patients for
trouble sleeping and low sleep quantity to
identify potential comorbidities and to more
effectively guide disease management. For
example, if a patient endorses trouble sleeping
or low sleep quantity, the physician could
consider comorbidities such as obesity, OSA,
and psychological symptoms. In some cases, a
referral to a sleep specialist may be necessary for
a more thorough evaluation of the many
nuanced factors that influence sleep [16].
Incorporating such screening into routine der-
matologic care seems not only manageable but
also essential given the well-established high
prevalence of sleep dysfunction in psoriasis as
well as the severe health outcomes associated
with this comorbidity in the psoriatic popula-
tion [1, 5, 7–11, 13, 21].
Moreover, several studies have examined
whether treatment of psoriasis alone is associ-
ated with improvements in sleep disturbance
among this population. Results have shown
that sleep problems can significantly improve
with successful treatment of psoriasis, leading
to reduced daytime fatigue and improved
quality of life [32, 33]. However, sleep dys-
function may not remit entirely even when
other psoriatic symptoms are well controlled,
especially if there are sleep-related comorbidi-
ties such as OSA [34]. These findings reinforce
the importance of screening psoriatic patients
for sleep problems and suggest that it may not
be sufficient to only treat psoriasis in patients
who endorse sleep disturbance.
In conclusion, this analysis helps fill the
critical need to better understand the many
associations of sleep disturbance in psoriasis
and derives from an innovative approach to
patient-centered research, whereby the psoriatic
population is directly involved in the design,
conduct, and analysis of the results [19]. While
this study has several limitations as discussed, a
key strength is overcoming selection bias that
can occur in sleep research since CP participants
were not selected on this basis, but rather
identified through a select subset of CP survey
answers. It is important to continue pioneering
and advocating for research like this that make
patients feel empowered and supported while
also giving researchers and clinicians greater
insight into many aspects of their lives with
psoriatic disease, including the impact on sleep
that has been thus far inadequately explored
given its many consequences.
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